Insight journal - Company

Novo Nordisk: Partnering activity 2005-2013

Posted on 20 August 2013

Tags: , , ,

Novo Nordisk announced over 60 partnering / licensing deals since 2005.

Abstracted from: Partnering Agreements with Novo Nordisk 2005-2013

The number of partnering, collaborative R&D and licensing deals announced varied year on year with a significant increase in 2008 before a return to normal levels thereafter.

The following figure shows the level of Novo Nordisk partnering deal announcements since 2005.

Figure 1: Novo Nordisk partnering deals 2005-2013

Novo Nordisk partnering activity by year

Source: Current Agreements, 2013

Analysis of the partnering deals shows a strong emphasis on partnerships in metabolic (diabetes specifically) and immunology diseases. This reflects the focus areas of Novo Nordisk strongly.

The following table provides an overview of the partnering deals announced by Novo Nordisk based on therapy area disclosed. Our report provides more detailed insight into the precise therapeutic target of each deal. See: Partnering Agreements with Novo Nordisk 2005-2013

Figure 2: Novo Nordisk partnering deals by therapy area 2005-2013

Novo Nordisk partnering activity by therapy

Source: Current Agreements, 2013

Further analysis of these deals shows that Novo Nordisk has a preference for licensing, collaborative R&D and development deals similar to many other big pharma companies. Such partnering deals provide the right for Novo Nordisk to exploit the licensors technology in return for payment of upfront, development and sales, and royalty payments.

The following table provides an overview of the partnering deals announced by Novo Nordisk based on deal type disclosed.

Figure 3: Novo Nordisk partnering deals by deal type 2005-2013

Novo Nordisk partnering activity by deal type

Source: Current Agreements, 2013

When looking at stage of development at partnering deal signing, the most popular stage at signing is discovery with 22 deal announcements.

Novo Nordisk is also active in partnering at preclinical and formulation stages. Such deals are of on-going importance to all top pharmaceutical and biotech companies as they seek to bolster their pipeline, fill gaps left as a result of drug candidates failing during clinical development, and ensure they have replacement products for when key drugs come off patent.

The following table provides an overview of the partnering deals announced by Novo Nordisk based on stage of development at signature.

Figure 4: Nov Nordisk partnering by stage of development 2005-2013

Novo Nordisk partnering activity by stage

Source: Current Agreements, 2013

The following table provides a summary of the top deals by headline value.

Figure 5: Top Novo Nordisk partnering deals by headline value 2005-2013

Novo Nordisk top partnering deals

Source: Current Agreements, 2013

Our report provides more detailed insight into the details of each deal. See: Partnering Agreements with Novo Nordisk 2005-2013

Novo Nordisk partnering at Current Agreements

View all partnering deals for Novo Nordisk:

2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005

Full details on each deal can be found at CurrentAgreements (subscription required)

Or purchase report: Partnering Agreements with Novo Nordisk 2005-2013

 

More

Company profile for Novo Nordisk 

Partnering interests for Novo Nordisk

No M&A activity recorded for Novo Nordisk

 

Available reports from Current Partnering

Report: Partnering Agreements with Novo Nordisk 2005-2013

Report: Partnering Deals and Alliances with Big Pharma

Report: Partnering Deals and Alliances with Big Biotech

 

Available resources for deal coverage for Novo Nordisk

Subscribe: Current Agreements life sciences partnering, M&A and financing deals database – find out more

Read: more on Novo Nordisk company profile, recent partnering, M&A and financing news and articles

 

Related

Report: Practical Guide to Finding Partners

View: Current Partnering’s Partnering Scorecard – view top life science partnering deals by value

View: Current Partnering’s M&A Scorecard – view top life science M&A deals by value

View: Current Partnering’s Deal Metrics – the latest deal trend infographics for life science deal making

View: Current Partnering’s Big Pharma Deal Making Scorecard – latest trends in big pharma deal making activity

View: Current Partnering’s Big Biotech Deal Making Scorecard – latest trends in big biotech deal making activity

View: Top 50 pharma – overview of top 50 pharmaceutical companies by revenue – partnering activity, deal news, partnering dealtalk

View: Top 50 biotech – overview of top 50 biotechnology companies by revenue – partnering activity, deal news, partnering dealtalk

Signup: Current Partnering Dealmakers Update – weekly newsletter providing the latest life science industry deal news, deal making trends, partnering events – sign up now

Signup: Current Agreements Deals Review – monthly newsletter - reviewing the previous month’s life science deal making – partnering, M&A and financing – sign up now

View: Top 50 pharma – overview of top 50 pharmaceutical companies by revenue – partnering activity, deal news, partnering dealtalk

View: Top 50 biotech – overview of top 50 biotechnology companies by revenue – partnering activity, deal news, partnering dealtalk

Print Friendly, PDF & Email

Leave a Reply